Sites of phosphorylation in tau and factors affecting their regulation - PubMed (original) (raw)
J Betts, W P Blackstock, J P Brion, S Chapman, J Connell, R Dayanandan, J M Gallo, G Gibb, D P Hanger, M Hutton, E Kardalinou, K Leroy, S Lovestone, T Mack, C H Reynolds, M Van Slegtenhorst
Affiliations
- PMID: 11447841
- DOI: 10.1042/bss0670073
Sites of phosphorylation in tau and factors affecting their regulation
B H Anderton et al. Biochem Soc Symp. 2001.
Abstract
The microtubule-associated protein, tau, is the principal component of paired helical filaments (PHFs) in Alzheimer's disease. PHF-tau is highly phosphorylated and a total of 25 sites of phosphorylation have so far been identified. Many of these sites are serine or threonine residues that are immediately followed in the sequence by proline residues, and hence are candidate phosphorylation sites for proline-directed kinases. In vitro, glycogen synthase kinase-3 (GSK-3), extracellular signal-related kinase-1 and -2, and mitogen-activated protein kinases, p38 kinase and c-jun N-terminal kinase, all phosphorylate many of these sites, although with different efficiencies for particular sites. Phosphorylation studies in transfected cells and neurons show that GSK-3 phosphorylates tau more extensively than do these other proline-directed kinases. Mutations in tau have been shown to affect in vitro phosphorylation of tau by GSK-3. The Arg406-->Trp (R406W) tau mutation also affects tau phosphorylation in cells.
Similar articles
- Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.
Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S, et al. Lovestone S, et al. Curr Biol. 1994 Dec 1;4(12):1077-86. doi: 10.1016/s0960-9822(00)00246-3. Curr Biol. 1994. PMID: 7704571 - Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK).
Yoshida H, Hastie CJ, McLauchlan H, Cohen P, Goedert M. Yoshida H, et al. J Neurochem. 2004 Jul;90(2):352-8. doi: 10.1111/j.1471-4159.2004.02479.x. J Neurochem. 2004. PMID: 15228592 - Microtubule-associated protein tau, paired helical filaments, and phosphorylation.
Mandelkow EM, Biernat J, Drewes G, Steiner B, Lichtenberg-Kraag B, Wille H, Gustke N, Mandelkow E. Mandelkow EM, et al. Ann N Y Acad Sci. 1993 Sep 24;695:209-16. doi: 10.1111/j.1749-6632.1993.tb23054.x. Ann N Y Acad Sci. 1993. PMID: 7694533 Review. - Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribé E, Dalfó E, Avila J. Ferrer I, et al. Curr Alzheimer Res. 2005 Jan;2(1):3-18. doi: 10.2174/1567205052772713. Curr Alzheimer Res. 2005. PMID: 15977985 Review.
Cited by
- Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation.
Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E. Rockenstein E, et al. J Neurosci. 2007 Feb 21;27(8):1981-91. doi: 10.1523/JNEUROSCI.4321-06.2007. J Neurosci. 2007. PMID: 17314294 Free PMC article. - Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss.
Rebeck GW, Hoe HS, Moussa CE. Rebeck GW, et al. J Biol Chem. 2010 Mar 5;285(10):7440-6. doi: 10.1074/jbc.M109.083915. Epub 2010 Jan 13. J Biol Chem. 2010. PMID: 20071340 Free PMC article. - Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.
Derkinderen P, Scales TM, Hanger DP, Leung KY, Byers HL, Ward MA, Lenz C, Price C, Bird IN, Perera T, Kellie S, Williamson R, Noble W, Van Etten RA, Leroy K, Brion JP, Reynolds CH, Anderton BH. Derkinderen P, et al. J Neurosci. 2005 Jul 13;25(28):6584-93. doi: 10.1523/JNEUROSCI.1487-05.2005. J Neurosci. 2005. PMID: 16014719 Free PMC article. - Tau as a therapeutic target for Alzheimer's disease.
Boutajangout A, Sigurdsson EM, Krishnamurthy PK. Boutajangout A, et al. Curr Alzheimer Res. 2011 Sep;8(6):666-77. doi: 10.2174/156720511796717195. Curr Alzheimer Res. 2011. PMID: 21679154 Free PMC article. Review. - Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease.
Morales-García JA, Susín C, Alonso-Gil S, Pérez DI, Palomo V, Pérez C, Conde S, Santos A, Gil C, Martínez A, Pérez-Castillo A. Morales-García JA, et al. ACS Chem Neurosci. 2013 Feb 20;4(2):350-60. doi: 10.1021/cn300182g. Epub 2012 Dec 5. ACS Chem Neurosci. 2013. PMID: 23421686 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous